GSK/Valeant's epilepsy drug Trobalt poised for EU approval
This article was originally published in Scrip
Executive Summary
European experts have recommended that the novel anti-epileptic Trobalt (retigabine), being developed by GlaxoSmithKline and Valeant Pharmaceuticals, should win approval in its first major market, the European Union.